Radioiodine Provides No Benefit After Thyroidectomy in Low-Risk Thyroid Cancer
Radioiodine after thyroidectomy did not improve outcomes in patients with low-risk thyroid cancer.
Endocrine Cancer
Peptide Receptor Radionuclide Therapy Prolongs PFS in Enteropancreatic Neuroendocrine Tumors
When compared with chemotherapy or targeted therapy, peptide receptor radionuclide therapy significantly prolonged progression-free survival.
Exploring a Potential Link Between Children With Obesity and Thyroid Cancer
Researchers hypothesized that a rising number of thyroid cancer rates in adults with obesity in may also imply an increase in thyroid cancer rates in children.
Selumetinib Does Not Improve CR Rate in Differentiated Thyroid Cancer
The complete response rate was similar for patients who received selumetinib and those who received radioactive iodine alone.
Pandemic-Related Decreases in Cancer Detection Persist for Some Cancers
The largest declines in incidence were seen for cervical, endocrine, and prostate cancers, as well as melanoma.
3MT Gene Signature May Predict Poor Outcomes in Neuroblastoma
Elevated urinary 3MT levels were tied to worse event-free and overall survival.
Recurrence of Papillary Thyroid Cancer Predicted by Genetic Risk Model
Analysis of messenger RNA, microRNA, and protein-encoding genes may predict the risk of papillary thyroid cancer recurrence.
Apatinib Improves PFS, OS in Radioactive Iodine-Refractory Thyroid Cancer
Apatinib improved progression-free survival regardless of baseline thyroglobulin levels.
Adding Monoclonal Antibody to Induction Could Be New Standard Care for High-Risk Neuroblastoma
Results from a phase 2 trial, if validated in a larger study, may be practice-changing, according to researchers.
¹⁷⁷Lu-Dotatate Provides ‘Clinically Relevant’ Improvement in Midgut Neuroendocrine Tumors
¹⁷⁷Lu-Dotatate improved the median overall survival by 11.7 months.
- Loading...
Loading...
Next post in Endocrine Cancer
Loading... 
Loading...